French
DeutschDimethyllysergamide
 | |
| Clinical data | |
|---|---|
| Other names | DAM-57; N,N-Dimethyllysergamide; DAM; Lysergic acid dimethylamide |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | hepatic |
| Excretion | renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C18H21N3O |
| Molar mass | 295.386 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
DAM-57, also known as N,N-dimethyllysergamide (DAM) or as lysergic acid dimethylamide, is a derivative of ergine. There has been a single report of observing N,N-dimethyl-D-lysergamide in the illicit drug market.[1] This compound did induce autonomic disturbances at oral levels of some ten times the dosage required for lysergic acid diethylamide (LSD), presumably in the high hundreds of micrograms. There is some disagreement as to whether there were psychic changes observed.[2] It was first described in the scientific literature by Albert Hofmann and colleagues by 1955.[3]
See also
[edit]References
[edit]- ^ Clark AB (1973). "Lysergic Acid Diethylamide and Lysergic Acid Dimethylamide". Microgram. 6: 37.
- ^ Shulgin A, Shulgin A (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. p. 26. ISBN 0-9630096-9-9. OCLC 38503252.; "#26. LSD-25". Erowid.
- ^ Hofmann A, Stoll A (1955). "Amide der stereoisomeren Lysergsäuren und Dihydro‐lysergsäuren. 38. Mitteilung über Mutterkornalkaloide" [Amides of stereoisomeric lysergic and dihydrolysergic acids. 38. Ergot alkaloids]. Helvetica Chimica Acta. 38 (2): 421–433. doi:10.1002/hlca.19550380207. ISSN 0018-019X. Retrieved 5 June 2025.
 | This hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |